Lv53
1280 积分 2024-04-24 加入
Post-marketing safety assessment of CAR T-cell therapies: Analysis of individual case safety reports in the VigiBase
9小时前
已完结
Real-world analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma
9小时前
已完结
Itacitinib for the prevention of IEC therapy-associated CRS: Results from the 2-part phase 2 INCB 39110-211 study
9小时前
已完结
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: A transplant complications and paediatric diseases working parties joint EBMT study
9小时前
已完结
Simple and early prediction of severe CAR-T-related adverse events after axi-cel infusion by initial high fever
9小时前
已完结
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
9小时前
已完结
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
14小时前
已完结
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
1天前
已完结
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
2个月前
已完结
ntraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108
2个月前
已完结
皖公网安备34019202002308
